

# HOXA9 Transcription Factor in AML

Subjects: **Oncology**

Contributor: Marie-Helene David-Cordonnier , Melanie LAMBERT , Samy Jambon , Isabelle Van Seuningen

HOXA9 (Homeobox A9) is a homeotic transcription factor known for more than two decades to be associated with leukemia. The expression of HOXA9 homeoprotein is associated with anterior–posterior patterning during embryonic development, and its expression is then abolished in most adult cells, with the exception of hematopoietic progenitor cells. The oncogenic function of HOXA9 was first assessed in human acute myeloid leukemia (AML), particularly in the mixed-phenotype associated lineage leukemia (MPAL) subtype. HOXA9 expression in AML is associated with aggressiveness and a poor prognosis. Since then, HOXA9 has been involved in other hematopoietic malignancies and an increasing number of solid tumors. Despite this, HOXA9 was for a long time not targeted to treat cancer, mainly since, as a transcription factor, it belongs to a class of protein long considered to be an “undruggable” target; however, things have now evolved.

HOXA9

acute myeloid leukemia

transcription factor

epigenetic

protein/protein interaction inhibitors

protein/DNA interaction inhibitors

## 1. Introduction

Transcription factors represent a large class of proteins with more than 1500 members, of which 15%–20% are considered oncogenes [1][2]. They are classified into more than 70 different families based on sequence and structure homologies of their DNA-binding domains. Among them, the homeobox DNA binding domain (homeodomain, HD) family encompasses more than 250 transcription factors, themselves subdivided into 21 different sub-families, including HOX-Like, Para-HOX, NK-Like, TALE (three amino acid loop extension) containing the PBC and MEIS groups among other), POU, HNF, LIM, Paired (PRD) and PRD-like subfamilies [3][4]. Derived from *Antennapedia* and *Bithorax* ancestors, the HOX-Like subgroup corresponds to the HOX cluster genes and is the only group of HD proteins conventionally named “HOX genes.” Organized into four paralog clusters in animals, the number and identity of HOX genes varies depending on the species. In humans, 39 HOX proteins are organized from 1 to 13 (as originally defined in *Drosophila*) in the four paralog clusters A to D. After their spatiotemporal expression, critical for patterning of the anterior–posterior axis in embryos, HOX gene expression is largely repressed in adults but controlled reactivation allows dynamic expression in adults to lead or reactivate some cellular processes, including hematopoiesis [5][6][7][8], wound healing [9][10], vascularization, endometrial development/fertility [11][12][13][14][15] and many other processes of body repair and homeostasis [16][17][18][19][20]. In particular, HOXA9 expression is finely controlled and decreases during the progression of normal hematopoiesis [21].

A large proportion of HOX cluster genes are considered oncogenes due to their implication in translocations, mutations or improper expression dynamics in some tissues. They are associated with cancer at the initiation, development or metastasis stages and are over-expressed in cancer cells relative to normal tissue (for reviews [\[22\]](#) [\[23\]](#)[\[24\]](#)[\[25\]](#)[\[26\]](#)[\[27\]](#)[\[28\]](#)[\[29\]](#)). As an example, the oncogenic function of HOXA cluster genes was originally well described in hematopoietic disorders. This is particularly the case of HOXA9 in acute myeloid leukemia (AML).

## 2. HOXA9: A Leukemic Driver in AML

The leukemogenic function of HOXA9 was first assessed in the murine model BXH-2, a mouse strain that spontaneously develops AML through endogenous retroviral integration. Indeed, Hoxa9, as well as a number of other Hox genes and its co-factor Meis1 (myeloid ecotropic viral integration site 1), are frequently over-expressed in BXH-2 murine leukemic cells [\[30\]](#). It was then evidenced that transplantation of cells over-expressing murine Hoxa9 by retroviral transduction evidenced a late onset of AML, a process that was accelerated by co-transduction with Meis1 [\[31\]](#).

In human leukemia, the first implication of HOXA9 was highlighted by the discovery of the NUP98-HOXA9 fusion protein resulting from t(7;11)(p15;p15) translocation [\[30\]](#)[\[32\]](#), a rare (1%–3%) AML subtype associated with poor prognosis [\[33\]](#)[\[34\]](#). NUP98, a nucleoporin of 98 kDa, is a chaperone protein associated with the nuclear pore. NUP98-HOXA9 binds directly to DNA on the HOXA9-cognate sequence via HOXA9 homeodomain [\[35\]](#). NUP98-HOXA9 chimera seems to induce myelodysplastic syndromes for a relatively long period before transformation in AML, a period that is reduced when MEIS1 is concomitantly expressed [\[36\]](#). The NUP98-HOXA9 protein would also have a higher transcriptional activity than HOXA9 itself due to its highest stability (half-life three times longer) in relation to its resistance to ubiquitinylation mediated by CUL-4A that may partly explain its oncogenic function [\[37\]](#).

Besides expressed as an oncogenic fused protein, the implication of structurally unmodified HOXA9 as a leukemic driver was then evidenced as part of its over-expression in leukemic cells. Indeed, the relevance of HOXA9 expression in global survival of human leukemia patients was first demonstrated on gene expression signatures relating to patient outcome: HOXA9 was evidenced as the protein presenting the highest correlation with poor prognosis in a series of nearly 7000 genes [\[38\]](#). This association of the level of HOXA9 expression with prognosis was also evaluated on an independent series of patients showing that low levels of HOXA9 (but also other HOXA and HOXB) gene expression is characteristic of a favorable cytogenetic AML subgroup [\[39\]](#)[\[40\]](#). Such general analyses now take into account the better knowledge of cytogenetic and molecular characteristics of different AML sub-types and it is now well established that HOXA9 over-expression is directly associated with some of them, themselves directly identified as good, intermediate, or adverse prognosis subgroups, with a total prevalence of ~70% of AML [\[41\]](#)[\[42\]](#). The main genetic alterations associated with HOXA9 over-expression in AML are presented in **Table 1**.


**Table 1.** List of the main genetic alterations in AML that are associated with HOXA9 over-expression.

Type of Alteration	Fusion/Mutation/Additional Chromosome	Translocation/Inversion/Deletion	References
Chromosomal alterations	MLL fusions	11q23 translocations	[43][44][45]
	NUP98-NSD1	t(5;11)(q35;p15)	[46][47]
	NUP98-HOXA9	t(7;11)(p15;p15)	[48]
	NUP98-HOXA10	t(7;11)(p15;p15)	[49]
	NUP98-HOXC11	t(11;12)(p15;q13)	[50]
	NUP98-HOXD11	t(2;11)(q31;p15)	[51]
	NUP98-HOXD13	t(2;11)(q31;p15)	[49]
	NUP98-HHEX	t(10;11)(q23;p15)	[52]
	NUP98-KDM5A	t(11;12)(p15;p13)	[33]
	NUP98-PHF23	t(11;17)(p15;p13)	[33]
Mutations	NUP98-PRRX1	t(1;11)(q24;p15)	[33]
	NUP98-DDX10	inv(11)(p15q22)	[33]
	MYST3-CREBBP	t(8;16)(p11;p13)	[53]
	RUNX1-EVI1	t(3;21)(q26;q22)	[54]
	CDX2-ETV6	t(12;13)(p13;q12)	[55]
	CALM-AF10	t(10;11)(p12-14;q14-21)	[56]
	SET-NUP214	del(9)(q34.11;q34.13)	[57]
	NPM1-MLF1	t(3;5)(q25;q34)	[58][59]
	+8	/	[60]
	NPM1		[61][62][63] [64]
MLL-PTD			[42]
DNMT3A			[65]
EZH2			[42]
IDH1/2			[63][66]

The most described HOXA9-associated leukemias are: (1) acute leukemia (either myeloid or lymphoid) bearing MLL (mixed lineage leukemia, also called KMT2A) fusions [43][68][44][69][45], known as mixed phenotype acute leukemia (MPAL), and which represent ~5% of AML and are associated with poor prognosis; and (2) AML with nucleophosmin 1 (NPM1) mutations, which represent ~55% of normal karyotype AML and ~35% of all AMLs, and

Type of Alteration	Fusion/Mutation/Additional Chromosome	Translocation/Inversion/Deletion References	such as
Polymorphism	GFI1-S36N	[61][62][63]	[67]

The AML subtype MPAL preferentially affects infants or is developed as a therapy-induced leukemia. MPAL is associated with poor prognosis with a five-year survival rate of less than 40% in infants compared to ~90% for non-MPAL [70]. The genomic breakpoints involve more than 130 different MLL translocation partners already described, with the 10 main partners representing >90% of the MLL translocations, including AF9 (~30%), AF10 (~16%), ELL (~10%), AF6 (~8%), and ENL (~6%) [71][72][73]. The major breakpoint cluster region is localized between exon 9 and intron 11 of the MLL gene in more than 80% of MPAL patients. These rearrangements generate a fusion between the N-terminal portion of the MLL protein containing its DNA binding domain and the carboxy-terminal portion of its protein partner [74]. The MLL protein will lose its SET domain and its domain for binding to ASB2, a ubiquitin ligase causing its proteolysis. Thereby, the fusion proteins generated will no more be degraded [75]. Interestingly, the main translocation partners (AF9/AF10/ENL), as well as minor partners such as AF4, are proteins that normally function within a large protein complex associated with the MLL protein (within a large complex or different sub-complexes). Translocations seem to physically fix proteins together in order to favor the stability and functionality of the MLL complex, particularly through interaction (direct or indirect) with the disruptor of telomeric silencing 1-like protein DOT1L (through direct interaction with AF10, for instance), an epigenetic partner that methylates lysine-79 residues of histone H3 proteins as a transcriptional activation mark [76][77][78], or with p-TEFb kinase (through direct interaction with AF4, for instance) that phosphorylates RNA polymerase II to allow gene transcription [79]. Among other proteins implicated in the active MLL complex are Menin [80][81], LEDGF (lens epithelium-derived growth factor) [80][82], WDR5 (WD repeat protein 5) [83], BRD4 (bromodomain-related protein 4) [84], HDAC (histone deacetylase) [85][86], KDM4C/JMJD2C (lysine-specific demethylase 4C/jumonji domain-containing protein 2C) and PRMT1 (protein arginine N-methyltransferase 1) [87] (Figure 1).



**Figure 1.** The different modes of regulation of HOXA9 expression and function in acute myeloid leukemia (AML). BRD4, bromodomain-related protein 4; CBP, CREB-binding protein; CDK9, cyclin-dependent kinase 9; D-2-HG, D-2-hydroxyglutarate; DHODH, dihydroorotate dehydrogenase; DNMT3A, DNA methyl transferase 3A; DOT1L, disruptor of telomeric silencing 1-like protein; HDAC, histone deacetylase; HEXIM1, hexamethylene bisacetamide (HMBA) inducible protein 1; HOXA9, homeobox A9; IDH, isocitrate dehydrogenase; KDM4C/lysine-specific demethylase 4C; LEDGF, lens epithelium-derived growth factor; LSD1, lysine-specific demethylase 1; MEIS1, myeloid ecotropic viral integration site 1; MLL, mixed lineage leukemia; MOF, males absent on the first; NPM1, nucleophosmin 1; NSD1, nuclear receptor binding SET domain protein 1; NUP98, nucleoporin 98kDa; PBX3, pre-B-cell leukemia transcription factor 3; PRMT1, protein arginine N-methyltransferase 1; pTEFb, positive transcription elongation factor b; SMAD4, mothers against decapentaplegic homolog 4; WDR5, WD repeat protein 5; XPO1, exportin-1.

In mice, grafting of bone marrow cells with retroviral transduction of MLL fusion proteins deregulated the expression of Hox genes [88]. All MPAL patients not only evidenced HOXA9 over-expression but also middle HOXA cluster over-expression, as exemplified by MLL-AF9 fusion, which positively regulates the expression of HOXA6, HOXA7, HOXA9, and HOXA10 [89]. MLL translocations also increase the expression of MEIS1, which is generally positively correlated with HOXA9 expression [29]. In addition, although the role of an alternative transcript HOXA9T is not clearly defined, HOXA9T is over-expressed in AMLs with MLL arrangements [90]. Beside these fusion proteins, partial tandem duplications (MLL-PTD) were discovered, particularly in de novo AML cases. The most common duplication event is a copy of exons 5-11 or 5-12 inserted into intron 4 and resulting in the replication of

the N-terminal portion of MLL that contains the AT-hook DNA binding domain. These alterations represent 12% of AML [72] and are associated with poor prognosis. By contrast, MPAL with MLL-PTD evidences moderate up-regulation of HOXA9 expression [91]; however, HOXA9 is still crucial for MLL-PTD-driven leukemogenic processes [42][92].

The NPM1 mutations are generally present in de novo adult AML with normal karyotype and were evidenced to be correlated with the over-expression of HOXA, MEIS1, and FLT3 genes [61][93]. Under normal conditions, NPM1 chaperone protein is located in the nucleus. NPM1 mutations result in the delocalization of the protein into the cytoplasm causing over-expression of HOXA9, HOXA10, and MEIS1 [62] by a mechanism probably associating MLL, P-TEFb, DOT1L, and/or menin [93][64]. One of the suggested mechanisms for mutated-NPM1 (also called NPM1c+) control of HOXA9 expression is the activation of the transcriptional complex P-TEFb (positive transcription elongation factor b), a partner of the MLL complex usually sequestered by HEXIM1 in the cytoplasm; HEXIM1 (hexamethylene bisacetamide (HMBA) inducible protein 1) sequestered in the cytoplasm by mutated-NPM1 could no longer interact with P-TEFb, which could therefore activate the MLL complex and subsequently HOXA9 expression [94][95] (Figure 2). Recently, it was also highlighted that NPM1c+ leukemic cell survival requires upregulation of HOXA9 and its DNA-binding partner, the Pre-B-cell leukemia homeobox 3 PBX3 in a MLL/DOT1L dependent manner [64].

**Figure 2.** Direct and indirect targeting of HOXA9 expression in AML: multiple epigenetic and non-epigenetic therapeutic opportunities.

In parallel, Brunetti et al. demonstrated that HOXA (and HOXB) genes are not only direct downstream targets of NPM1c+ protein but also that the interaction between exportin-1 (XPO-1), a nuclear pore exporter, and NPM1c+ protein, maintains mutated-NPM1 in the cytoplasmic compartment as an important point explaining AML occurrence [96]. Moreover, Gu et al. [97] evidenced NPM1c+ interaction with PU.1/SPI1 transcription factor as another way to maintain NPM1 within this complex in the cytoplasm, whereas PU.1 over-expression is associated with a decrease in HOXA gene expression.

The over-expression of HOXA9 is also found in many NUP98 fusions containing AML samples, accounting for a total of 1%–3% of AML [33]. Some examples are presented in **Table 1**. A lot of these partners are associated with epigenetic control or the DNA binding function (with, for instance, a lot of homeodomain containing transcription factor partners). The most frequent of these is the H3K36 methyltransferase NSD1 (nuclear receptor binding SET domain protein 1), forming the NUP98-NSD1 fusion protein that activates HOXA gene expression for leukemogenesis in 1%–2% AML [46].

Trisomy 8 (+8) represents ~10% of all AML and also correlates with a high level of HOXA9 expression [60]. Alone, trisomy 8 is not sufficient for leukemogenesis but is often associated with the t(7;12) or t(9;11) and t(1;11) MLL translocations. HOXA9 and HOXA10 are the first and second rated over-expressed genes in +8 AML, respectively, relative to normal bone marrow cells [60]. However, this analysis does not exclude MPAL and +8 double positive

AML, and further analysis may be required to ensure that MLL alteration was not the main driver of HOXA9/10 over-expression in +8 AML.

In many other well-defined cytogenetic or molecular alterations associated with AML, HOXA9 can be frequently over-expressed but not in all patients of the same sub-group, suggesting that further analysis of additional alteration would be required. For instance, EVI1 over-expressing leukemia results from t(3;21)(q26;q22) associated with poor survival in 8%–10% AML and presents over-expression of the HOXA9 gene with a large spread of HOXA9 expression from positive to negative.

In total, the proportion of HOXA9-over-expressed AML is ~70%. This high proportion highlights HOXA9 as an interesting potential target to treat such AML.

The oncogenic function of HOXA9 in AML is associated with cell proliferation, differentiation blockade, increased malignancy of leukemic cells, and progenitor self-renewal maintenance [98]. Invalidation of HOXA9 expression in those cells impairs proliferation and leukemic properties, and re-activates differentiation processes, showing that HOXA9 is a functional target to restore differentiation in AML [45][99][100][101]. More precisely, the presence of the HOXA9 DNA binding domain is a prerequisite for HOXA9-induced leukemic transformation in mice models: (i) swapping HOXA9 homeodomain with HOXA1 homeodomain in the HOXA9 transcription factor is sufficient to abolish the leukemic potential of transduced murine hematopoietic progenitor cells engrafted in mice, whereas transferring HOXA9 homeodomain in the HOXA1 protein maintains the leukemic propensity of HOXA9 and results in common deregulated gene signatures with wild-type HOXA9-induced transformation [102]; (ii) mutating HOXA9 homeodomain at Asn51 to a serine residue (N51S) abolishes leukemic transformation in mice [103][104]. Similarly, HOXA9T, a splice variant protein which has lost its DNA binding domain, does not induce leukemia by itself, even if it seems to support the leukemogenic activity of HOXA9 [105] by a yet unclear mechanism of action, but may imply HOXA9T binding to transcription promoting factors such as CBP (CREB-binding protein) or some chaperone proteins [106]. Interestingly, the phosphorylation status of HOXA9 changes its DNA binding activity and consequently its propensity to induce leukemia, as demonstrated with protein kinase C (PKC) phosphorylation of Ser204 of the HOXA9 DNA binding domain, impairing DNA binding and leading to myeloid differentiation of murine Hoxa9-immortalized bone marrow cells [107].

In order to understand HOXA9-mediated leukemogenesis, the key point would be to identify the network underlying its transcriptional activity using ChIP-sequencing. However, due to the lack of ChIP and ChIP-seq grade antibodies directed against HOXA9 and other HOX proteins to identify endogenous targets for each HOX protein on the chromatin, most global ChIP analyses have used exogenous expression of tagged proteins. This is notably the case of a HA-tagged Hoxa9 protein in a Hoxa9- and Meis1-transformed murine bone marrow cell model to identify thousands of genomic binding regions of the murine Hoxa9 transcription factor, being associated or not with Meis. These studies identified several pro-leukemic Hoxa9 target genes such as Erg (ETS-related gene), Flt3, Lmo2 (LIM domain only 2), and c-Myb (myeloblastosis) [108]. However, a recent study has shown that Hoxa9 is a specific substrate of a granule protease and that its inhibition would allow the ChIP-sequencing analysis in primary

transformed murine cells, showing a feedback loop driving expression of key oncogenes and cell cycle control genes [109].

Alternatively, microarray or RNA-seq analyzes have been successfully performed. Gene expression analyses in models over-expressing or interfering (shRNA, CRISPR9-Cas9) with HOXA9 expression showed significant transcriptomic modulations in which HOXA9 could act as an activator or a repressor, depending on target gene and cell context [110]. Most HOXA9-specific targets were also discovered individually, including Lmo2, Bcl-2, Fgf2, Igf1, Ink4a/b, and c-Myb [108][110][111][112][113][114][115][116]. In particular, HOXA9 functions as a pioneer factor at de novo enhancers and recruits CEBP $\alpha$  and the MLL3/MLL4 complex [117]. HOXA9 over-expression in progenitor cells, therefore, leads to significant enhancer reorganizations with prominent emergence of leukemia-specific de novo enhancers.

If HOXA9 could act alone to trigger leukemia, it requires cofactors to increase its propensity to induce leukemia. For HOXA9, the leukemogenic activity of MEIS1 was discovered through in vivo experiments in BXH-2 mice, a pro-viral insertion model in which 15% of induced AMLs are caused by pro-viral insertion into the Meis1 gene locus [118]. Like HOXA9, Meis1 expression decreases during normal differentiation of blood cells. In vivo, the presence of Hoxa9 expressed alone in murine bone marrow cells is not sufficient to rapidly induce leukemia (>6 months) whereas concomitant expression of Hoxa9 with Meis1 greatly shortened this period (approximately 67 days). However, Meis1 alone does not induce leukemia [31], Meis1 as an accelerator of Hoxa9-induced leukemia but not stricto sensu as an oncogene. In human AML samples, a correlation expression of MEIS1 and HOXA9 is observed, suggesting a parallel or common temporal action of these factors [30][119][120]. If MEIS1 potentiates the leukemia action of HOXA9, this is also the case of PBX3, whose expression is also strongly correlated with HOXA9 expression, especially in leukemia subtypes with a normal karyotype or associated with MLL rearrangements. The overexpression of PBX3 and HOXA9 thus favors the initiation and implantation of AML [29]. Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation also represses NPM1c+ leukemic cell survival [64].

As HOXA9 is associated with a large proportion of AML, its inhibition is an interesting strategy against AML that could be achieved by different ways:

- inhibition of its expression;
- blockade of the specific protein/protein interaction crucial for its mechanism of action;
- or, more specifically as part of a transcription factor, the blockade of the interaction with its cognate sequence on the DNA.

## References

1. Vaquerizas, J.M.; Kummerfeld, S.K.; Teichmann, S.A.; Luscombe, N.M. A census of human transcription factors: Function, expression and evolution. *Nat. Rev. Genet.* 2009, 10, 252–263.
2. Lambert, M.; Jambon, S.; Depauw, S.; David-Cordonnier, M.-H. Targeting transcription factors for cancer treatment. *Molecules* 2018, 23, 1479.
3. Vaquerizas, J.M.; Akhtar, A.; Luscombe, N.M. Large-Scale Nuclear Architecture and Transcriptional Control. *Subcell. Biochem.* 2011, 52, 279–295.
4. Gehring, W.J.; Affolter, M.; Burglin, T. Homeodomain Proteins—Annual Review of Biochemistry. *Annu. Rev. Biochem.* 1994, 63, 6487–6526.
5. Lawrence, H.J.; Sauvageau, G.; Humphries, R.K.; Largman, C. The role of HOX homeobox genes in normal and leukemic hematopoiesis. *Stem Cells* 1996, 14, 281–291.
6. Van Oostveen, J.W.; Bijl, J.J.; Raaphorst, F.M.; Walboomers, J.J.M.; Meijer, C.J.L.M. The role of Homeobox genes in normal hematopoiesis and hematological malignancies. *Leukemia* 1999, 13, 1675–1690.
7. Argiropoulos, B.; Humphries, R.K. Hox genes in hematopoiesis and leukemogenesis. *Oncogene* 2007, 26, 6766–6776.
8. Alharbi, R.A.; Pandha, H.S.; Simpson, G.R.; Pettengell, R.; Poterlowicz, K.; Thompson, A.; Harrington, K.; El-Tanani, M.; Morgan, R. Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. *Oncotarget* 2017, 8, 89566–89579.
9. Wang, K.C.; Helms, J.A.; Chang, H.Y. Regeneration, repair and remembering identity: The three Rs of Hox gene expression. *Trends Cell Biol.* 2009, 19, 268–275.
10. Kachgal, S.; Mace, K.A.; Boudreau, N.J. The dual roles of homeobox genes in vascularization and wound healing. *Cell Adhes. Migr.* 2012, 6, 457–470.
11. Taylor, H.S. The Role of HOX Genes in the Development and Function of the Female Reproductive Tract. *Semin. Reprod. Med.* 2002, 18, 081–090.
12. Akbas, G.E.; Taylor, H.S. HOXC and HOXD Gene Expression in Human Endometrium: Lack of Redundancy with HOXA Paralogs1. *Biol. Reprod.* 2004, 70, 39–45.
13. Hughes, I.A.; Acerini, C.L. Factors controlling testis descent. *Eur. J. Endocrinol.* 2008, 159, S75–S82.
14. Raines, A.M.; Adam, M.; Magella, B.; Meyer, S.E.; Grimes, H.L.; Dey, S.K.; Potter, S.S. Recombineering-based dissection of flanking and paralogous Hox gene functions in mouse reproductive tracts. *Development* 2013, 140, 2942–2952.
15. Du, H.; Taylor, H.S. The role of hox genes in female reproductive tract development, adult function, and fertility. *Cold Spring Harb. Perspect. Med.* 2016, 6, 023002.

16. Awgulewitsch, A. Hox in hair growth and development. *Naturwissenschaften* 2003, 90, 193–211.
17. Freschi, G.; Taddei, A.; Bechi, P.; Faiella, A.; Gulisano, M.; Cillo, C.; Bucciarelli, G.; Boncinelli, E. Expression of HOX homeobox genes in the adult human colonic mucosa (and colorectal cancer?). *Int. J. Mol. Med.* 2005, 16, 581–587.
18. Mahdipour, E.; Mace, K.A. Hox transcription factor regulation of adult bone-marrow-derived cell behaviour during tissue repair and regeneration. *Expert Opin. Biol. Ther.* 2011, 11, 1079–1090.
19. Rux, D.R.; Wellik, D.M. Hox genes in the adult skeleton: Novel functions beyond embryonic development. *Dev. Dyn.* 2017, 246, 310–317.
20. Dunwell, T.L.; Holland, P.W.H. Diversity of human and mouse homeobox gene expression in development and adult tissues. *BMC Dev. Biol.* 2016, 16, 1–9.
21. Pineault, N.; Helgason, C.D.; Lawrence, H.J.; Humphries, R.K. Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. *Exp. Hematol.* 2002, 30, 49–57.
22. Barba, P.; Magli, M.C.; Tiberio, C.C.C. HOX gene expression in human cancers. *Adv. Exp. Med. Biol.* 1993, 348, 45–57.
23. Cillo, C. HOX genes in human cancers. *Invasion Metastasis* 1994, 14, 38–49.
24. Goodman, F.R.; Scambler, P.J. Human HOX gene mutations. *Clin. Genet.* 2001, 59, 1–11.
25. Cantile, M.; Franco, R.; Schiavo, G.; Procino, A.; Cindolo, L.; Botti, G. The HOX genes network in uro-genital cancers: Mechanisms and potential therapeutic implications. *Curr. Med. Chem.* 2011, 18, 4872–4884.
26. Morgan, R.; El-Tanani, M. HOX Genes as Potential Markers of Circulating Tumour Cells. *Curr. Mol. Med.* 2016, 16, 322–327.
27. Bhatlekar, S.; Fields, J.Z.; Boman, B.M. Role of HOX Genes in Stem Cell Differentiation and Cancer. *Stem Cells Int.* 2018, 2018, 1–15.
28. Li, B.; Huang, Q.; Wei, G.-H. The Role of HOX Transcription Factors in Cancer Predisposition and Progression. *Cancers* 2019, 11, 528.
29. Li, Z.; Chen, P.; Su, R.; Hu, C.; Li, Y.; Elkahloun, A.G.; Zuo, Z.; Gurbuxani, S.; Arnovitz, S.; Weng, H.; et al. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease. *Cancer Res.* 2016, 76, 619–629.
30. Nakamura, T.; Largaespada, D.A.; Lee, M.P.; Johnson, L.A.; Ohyashiki, K.; Toyama, K.; Chen, S.J.; Willman, C.L.; Chen, I.M.; Feinberg, A.P.; et al. Fusion of the nucleoporin gene NUP98 to

- HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. *Nat. Genet.* 1996, 12, 154–158.
31. Kroon, E.; Krosi, J.; Thorsteinsdottir, U.; Baban, S.; Buchberg, A.M.; Sauvageau, G. HOXA9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. *EMBO J.* 1998, 17, 3714–3725.
32. Borrow, J.; Shearman, A.M.; Stanton, V.P.; Becher, R.; Collins, T.; Williams, A.J.; Dubé, I.; Katz, F.; Kwong, Y.L.; Morris, C.; et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. *Nat. Genet.* 1996, 12, 159–167.
33. Gough, S.M.; Slape, C.I.; Aplan, P.D. NUP98 gene fusions and hematopoietic malignancies: Common themes and new biologic insights. *Blood* 2011, 118, 6247–6257.
34. Rio-Machin, A.; Gómez-López, G.; Muñoz, J.; Garcia-Martinez, F.; Maiques-Diaz, A.; Alvarez, S.; Salgado, R.N.; Shrestha, M.; Torres-Ruiz, R.; Haferlach, C.; et al. The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia. *Leukemia* 2017, 32, 2000–2005.
35. Kasper, L.H.; Brindle, P.K.; Schnabel, C.A.; Pritchard, C.E.J.; Cleary, M.L.; van Deursen, J.M.A. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. *Mol. Cell. Biol.* 1999, 19, 764–776.
36. Kroon, E.; Thorsteinsdottir, U.; Mayotte, N.; Nakamura, T.; Sauvageau, G. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. *EMBO J.* 2001, 20, 350–361.
37. Zhang, Y.; Morrone, G.; Zhang, J.; Chen, X.; Lu, X.; Ma, L.; Moore, M.; Zhou, P. CUL-4A stimulates ubiquitylation and degradation of the HOXA9 homeodomain protein. *EMBO J.* 2003, 22, 6057–6067.
38. Golub, T.R.; Slonim, D.K.; Tamayo, P.; Huard, C.; Gaasenbeek, M.; Mesirov, J.P.; Coller, H.; Loh, M.L.; Downing, J.R.; Caligiuri, M.A.; et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. *Science* 1999, 286, 531–537.
39. Debernardi, S.; Lillington, D.M.; Chaplin, T.; Tomlinson, S.; Amess, J.; Rohatiner, A.; Lister, T.A.; Young, B.D. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. *Genes Chromosom.* 2003, 37, 149–158.
40. Andreeff, M.; Ruvolo, V.; Gadgil, S.; Zeng, C.; Coombes, K.; Chen, W.; Kornblau, S.; Barón, A.E.; Drabkin, H.A. HOX expression patterns identify a common signature for favorable AML. *Leukemia* 2008, 22, 2041–2047.
41. Braekeleer, E.D.; Douet-Guilbert, N.; Basinko, A.; Bris, M.J.L.; Morel, F.; De Braekeleer, M. Hox gene dysregulation in acute myeloid leukemia. *Futur. Oncol.* 2014, 10, 475–495.

42. Gao, L.; Sun, J.; Liu, F.; Zhang, H.; Ma, Y. Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia. *Onco. Targets Ther.* 2016, 9, 711–722.
43. Kawagoe, H.; Humphries, R.K.; Blair, A.; Sutherland, H.J.; Hogge, D.D. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. *Leukemia* 1999, 13, 687–698.
44. Ferrando, A.A.; Armstrong, S.A.; Neuberg, D.S.; Sallan, S.E.; Silverman, L.B.; Korsmeyer, S.J.; Look, A.T. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: Dominance of HOX dysregulation. *Blood* 2003, 102, 262–268.
45. Faber, J.; Krivtsov, A.V.; Stubbs, M.C.; Wright, R.; Davis, T.N.; van den Heuvel-Eibrink, M.; Zwaan, C.M.; Kung, A.L.; Armstrong, S.A. HOXA9 is required for survival in human MLL-rearranged acute leukemias. *Blood* 2009, 113, 2375–2385.
46. Wang, G.G.; Cai, L.; Pasillas, M.P.; Kamps, M.P. NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. *Nat. Cell Biol.* 2007, 9, 804–812.
47. Kivioja, J.L.; Lopez Martí, J.M.; Kumar, A.; Kontro, M.; Edgren, H.; Parsons, A.; Lundán, T.; Wolf, M.; Porkka, K.; Heckman, C.A. Chimeric NUP98–NSD1 transcripts from the cryptic t(5;11) (q35.2;p15.4) in adult de novo acute myeloid leukemia. *Leuk. Lymphoma* 2018, 59, 725–732.
48. Ghannam, G.; Takeda, A.; Camarata, T.; Moore, M.A.; Viale, A.; Yaseen, N.R. The oncogene Nup98-HOXA9 induces gene transcription in myeloid cells. *J. Biol. Chem.* 2004, 279, 866–875.
49. Palmqvist, L.; Pineault, N.; Wasslavik, C.; Humphries, R.K. Candidate genes for expansion and transformation of hematopoietic stem cells by NUP98-HOX fusion genes. *PLoS ONE* 2007, 2, e768.
50. Taketani, T.; Taki, T.; Shibuya, N.; Kikuchi, A.; Hanada, R.; Hayashi, Y. Novel NUP98-HOXC11 fusion gene resulted from a chromosomal break within exon 1 of HOXC11 in acute myeloid leukemia with t(11;12)(p15;q13). *Cancer Res.* 2002, 62, 4571–4574.
51. Taketani, T.; Taki, T.; Shibuya, N.; Hayashi, Y.; Taketani, T.; Ito, E.; Kitazawa, J.; Terui, K. The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11)(q31;p15). *Cancer Res.* 2002, 62, 33–37.
52. Jankovic, D.; Gorello, P.; Liu, T.; Ehret, S.; La Starza, R.; Desjobert, C.; Baty, F.; Brutsche, M.; Jayaraman, P.S.; Santoro, A.; et al. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia. *Blood* 2008, 111, 5672–5682.
53. Camós, M.; Esteve, J.; Jares, P.; Colomer, D.; Rozman, M.; Villamor, N.; Costa, D.; Carrió, A.; Nomdedéu, J.; Montserrat, E.; et al. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. *Cancer Res.* 2006, 66, 6947–6954.

54. Jin, G.; Yamazaki, Y.; Takuwa, M.; Takahara, T.; Kaneko, K.; Kuwata, T.; Miyata, S.; Nakamura, T. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. *Blood* 2007, 109, 3998–4005.
55. Chase, A.; Reiter, A.; Burci, L.; Cazzaniga, G.; Biondi, A.; Pickard, J.; Roberts, I.A.; Goldman, J.M.; Cross, N.C. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). *Blood* 1999, 93, 1025–1031.
56. Novak, R.L.; Harper, D.P.; Caudell, D.; Slape, C.; Beachy, S.H.; Aplan, P.D. Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes. *Exp. Hematol.* 2012, 40, 1016–1027.
57. Van Vlierberghe, P.; Van Grotel, M.; Tchinda, J.; Lee, C.; Beverloo, H.B.; Van Der Spek, P.J.; Stubbs, A.; Cools, J.; Nagata, K.; Fornerod, M.; et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. *Blood* 2008, 111, 4668–4680.
58. Dumezy, F.; Preudhomme, C.; Nibourel, O.; Labis, E.; Renneville, A.; Mayeur-Rousse, C. Acute myeloid leukemia with translocation t(3;5): New molecular insights. *Haematologica* 2013, 98, e52–e54.
59. Lim, G.; Choi, J.R.; Kim, M.J.; Kim, S.Y.; Lee, H.J.; Suh, J.T.; Yoon, H.J.; Lee, J.; Lee, S.; Lee, W.I.; et al. Detection of t(3;5) and NPM1/MLF1 rearrangement in an elderly patient with acute myeloid leukemia: Clinical and laboratory study with review of the literature. *Cancer Genet. Cytogenet.* 2010, 199, 101–109.
60. Kok, C.H.; Brown, A.L.; Ekert, P.G.; D'Andrea, R.J. Gene expression analysis reveals HOX gene upregulation in trisomy 8 AML. *Leukemia* 2010, 24, 1239–1243.
61. Alcalay, M.; Tiacci, E.; Bergomas, R.; Bigerna, B.; Venturini, E.; Minardi, S.P.; Meani, N.; Diverio, D.; Bernard, L.; Tizzoni, L.; et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. *Blood* 2005, 106, 899–902.
62. Mullighan, C.G.; Kennedy, A.; Zhou, X.; Radtke, I.; Phillips, L.A.; Shurtleff, S.A.; Downing, J.R. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. *Leukemia* 2007, 21, 2000–2009.
63. Ogawara, Y.; Katsumoto, T.; Aikawa, Y.; Shima, Y.; Kagiyama, Y.; Soga, T.; Matsunaga, H.; Seki, T.; Araki, K.; Kitabayashi, I. IDH2 and NPM1 mutations cooperate to activate Hoxa9/Meis1 and Hypoxia pathways in acute myeloid Leukemia. *Cancer Res.* 2015, 75, 2005–2016.

64. Zhang, W.; Zhao, C.; Zhao, J.; Zhu, Y.; Weng, X.; Chen, Q.; Sun, H.; Mi, J.Q.; Li, J.; Zhu, J.; et al. Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival. *Theranostics* 2018, 8, 4359–4371.
65. Koya, J.; Kataoka, K.; Sato, T.; Bando, M.; Kato, Y.; Tsuruta-Kishino, T.; Kobayashi, H.; Narukawa, K.; Miyoshi, H.; Shirahige, K.; et al. DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. *Nat. Commun.* 2016, 7, 10924.
66. Chaturvedi, A.; Araujo Cruz, M.M.; Jyotsana, N.; Sharma, A.; Yun, H.; Görlich, K.; Wichmann, M.; Schwarzer, A.; Preller, M.; Thol, F.; et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. *Blood* 2013, 122, 2877–2887.
67. Botezatu, L.; Michel, L.C.; Helness, A.; Vadnais, C.; Makishima, H.; Hönes, J.M.; Robert, F.; Vassen, L.; Thivakaran, A.; Al-Matary, Y.; et al. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. *Exp. Hematol.* 2016, 44, 713–726.
68. Rozovskaia, T.; Feinstein, E.; Mor, O.; Foa, R.; Blechman, J.; Nakamura, T.; Croce, C.M.; Cimino, G.; Canaani, E. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4: 11) abnormality. *Oncogene* 2001, 20, 874–878.
69. Ayton, P.M.; Cleary, M.L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. *Genes Dev.* 2003, 17, 2298–2307.
70. Slany, R.K. The molecular biology of mixed lineage leukemia. *Haematologica* 2009, 94, 984–993.
71. Meyer, C.; Kowarz, E.; Hofmann, J.; Renneville, A.; Zuna, J.; Trka, J.; Ben Abdelali, R.; Macintyre, E.; De Braekeleer, E.; De Braekeleer, M.; et al. New insights to the MLL recombinome of acute leukemias. *Leukemia* 2009, 23, 1490–1499.
72. Meyer, C.; Burmeister, T.; Gröger, D.; Tsaur, G.; Fechina, L.; Renneville, A.; Sutton, R.; Venn, N.C.; Emerenciano, M.; Pombo-De-Oliveira, M.S.; et al. The MLL recombinome of acute leukemias in 2017. *Leukemia* 2018, 32, 273–284.
73. Marschalek, R. Mechanisms of leukemogenesis by MLL fusion proteins. *Br. J. Haematol.* 2011, 152, 141–154.
74. Muntean, A.G.; Hess, J.L. The Pathogenesis of Mixed-Lineage Leukemia. *Annu. Rev. Pathol. Mech. Dis.* 2011, 7, 283–301.
75. Muntean, A.G.; Tan, J.; Sitwala, K.; Huang, Y.; Bronstein, J.; Connelly, J.A.; Basrur, V.; Elenitoba-Johnson, K.S.J.; Hess, J.L. The PAF Complex Synergizes with MLL Fusion Proteins at HOX Loci to Promote Leukemogenesis. *Cancer Cell* 2010, 17, 609–621.
76. Nguyen, T.H.; Rossetti, G.; Arnesano, F.; Ippoliti, E.; Natile, G.; Carloni, P. Molecular recognition of platinated DNA from chromosomal HMGB1. *J. Chem. Theory Comput.* 2014, 10, 3578–3584.

77. Okuda, H.; Stanojevic, B.; Kanai, A.; Kawamura, T.; Takahashi, S.; Matsui, H.; Takaori-Kondo, A.; Yokoyama, A. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia. *J. Clin. Investig.* 2017, 127, 1918–1931.
78. Wood, K.; Tellier, M.; Murphy, S. DOT1L and H3K79 Methylation in Transcription and Genomic Stability. *Biomolecules* 2018, 8, 11.
79. Price, D.H. P-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II. *Mol. Cell. Biol.* 2002, 20, 2629–2634.
80. Yokoyama, A.; Cleary, M.L. Menin Critically Links MLL Proteins with LEDGF on Cancer-Associated Target Genes. *Cancer Cell* 2008, 14, 36–46.
81. Thiel, A.T.; Huang, J.; Lei, M.; Hua, X. Menin as a hub controlling mixed lineage leukemia. *BioEssays* 2012, 34, 771–780.
82. El Ashkar, S.; Schwaller, J.; Pieters, T.; Goossens, S.; Demeulemeester, J.; Christ, F.; Van Belle, S.; Juge, S.; Boeckx, N.; Engelman, A.; et al. LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. *Blood* 2018, 131, 95–107.
83. Ge, Z.; Song, E.J.; Kawasawa, Y.I.; Li, J.; Dovat, S.; Song, C.; Ge, Z.; Song, E.J.; Kawasawa, Y.I.; Li, J.; et al. WDR5 high expression and its effect on tumorigenesis in leukemia. *Oncotarget* 2016, 7, 37740–37754.
84. Deshpande, A.J.; Chen, L.; Fazio, M.; Sinha, A.U.; Bernt, K.M.; Banka, D.; Dias, S.; Chang, J.; Olhava, E.J.; Daigle, S.R.; et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. *Blood* 2013, 121, 2533–2541.
85. Ahmad, K.; Katryniok, C.; Scholz, B.; Merkens, J.; Löscher, D.; Marschalek, R.; Steinhilber, D. Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL. *Oncogenesis* 2014, 3, e127.
86. Matthews, G.M.; Mehdipour, P.; Cluse, L.A.; Falkenberg, K.J.; Wang, E.; Roth, M.; Santoro, F.; Vidacs, E.; Stanley, K.; House, C.M.; et al. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. *Blood* 2015, 126, 2392–2403.
87. Cheung, N.; Fung, T.K.; Zeisig, B.B.; Holmes, K.; Rane, J.K.; Mowen, K.A.; Finn, M.G.; Lenhard, B.; Chan, L.C.; So, C.W.E. Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia. *Cancer Cell* 2016, 29, 32–48.
88. Yu, B.D.; Hess, J.L.; Horning, S.E.; Brown, G.A.J.; Korsmeyer, S.J. Altered Hox expression and segmental identity in Mll-mutant mice. *Nature* 1995, 378, 505–508.
89. Krivtsov, A.V.; Twomey, D.; Feng, Z.; Stubbs, M.C.; Wang, Y.; Faber, J.; Levine, J.E.; Wang, J.; Hahn, W.C.; Gilliland, D.G.; et al. from committed progenitor to leukaemia stem cell initiated by MLL-AF9. *Nature* 2006, 442, 818–822.

90. He, M.; Chen, P.; Arnovitz, S.; Li, Y.; Huang, H.; Neilly, M.B.; Wei, M.; Rowley, J.D.; Chen, J.; Li, Z. Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia. *Blood Cells Mol. Dis.* 2012, 49, 102–106.
91. Zorko, N.A.; Bernot, K.M.; Whitman, S.P.; Siebenaler, R.F.; Ahmed, E.H.; Marcucci, G.G.; Yanes, D.A.; McConnell, K.K.; Mao, C.; Kalu, C.; et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. *Blood* 2012, 120, 1130–1136.
92. Whitman, S.P.; Liu, S.; Vukosavljevic, T.; Rush, L.J.; Yu, L.; Liu, C.; Klisovic, M.I.; Maharry, K.; Guimond, M.; Strout, M.P.; et al. The MLL partial tandem duplication: Evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. *Blood* 2005, 106, 345–352.
93. Kühn, M.W.M.; Song, E.; Feng, Z.; Sinha, A.; Chen, C.W.; Deshpande, A.J.; Cusan, M.; Farnoud, N.; Mupo, A.; Grove, C.; et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. *Cancer Discov.* 2016, 6, 1166–1181.
94. Gurumurthy, M.; Tan, C.H.; Ng, R.; Zeiger, L.; Lau, J.; Lee, J.; Dey, A.; Philp, R.; Li, Q.; Lim, T.M.; et al. Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. *J. Mol. Biol.* 2008, 378, 302–317.
95. Monroe, S.C.; Jo, S.Y.; Sanders, D.S.; Basrur, V.; Elenitoba-Johnson, K.S.; Slany, R.K.; Hess, J.L. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. *Exp. Hematol.* 2011, 39, 77–86.
96. Brunetti, L.; Gundry, M.C.; Sorcini, D.; Guzman, A.G.; Huang, Y.H.; Ramabadran, R.; Gionfriddo, I.; Mezzasoma, F.; Milano, F.; Nabet, B.; et al. Mutant NPM1 Maintains the Leukemic State through HOX Expression. *Cancer Cell* 2018, 34, 499–512.
97. Gu, X.; Ebrahem, Q.; Mahfouz, R.Z.; Hasipek, M.; Enane, F.; Radivoyevitch, T.; Rapin, N.; Przychodzen, B.; Hu, Z.; Balusu, R.; et al. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. *J. Clin. Investig.* 2018, 128, 4260–4279.
98. Chen, S.; Yu, J.; Lv, X.; Zhang, L. HOXA9 is critical in the proliferation, differentiation, and malignancy of leukaemia cells both in vitro and in vivo. *Cell Biochem. Funct.* 2017, 35, 433–440.
99. Li, A.; Yang, Y.; Gao, C.; Lu, J.; Jeong, H.W.; Liu, B.H.; Tang, P.; Yao, X.; Neuberg, D.; Huang, G.; et al. A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis. *J. Clin. Investig.* 2013, 123, 4195–4207.
100. Dickson, G.; Liberante, F.; Kettyle, L.; O'Hagan, K.; Finnegan, D.; Bullinger, L.; Geerts, D.; McMullin, M.F.; Lappin, T.; Mills, K.; et al. HOXA/PBX3 knockdown impairs growth and sensitizes

- cytogenetically normal acute myeloid leukemia cells to chemotherapy. *Haematologica* 2013, 98, 1216–1225.
101. Lambert Jambon, S.; Depauw, S.; Bouhlel, M.A.; Figeac, M.; David-Cordonnier, M.-H. HOXA9 transcription factor as a target in acute myeloid leukemia: Transcription, cellular and in vivo consequences of its invalidation. *Eur. J. Cancer* 2016, 69, S23.
102. Breitinger, C.; Maethner, E.; Garcia-Cuellar, M.P.; Slany, R.K. The homeodomain region controls the phenotype of HOX-induced murine leukemia. *Blood* 2012, 120, 4018–4027.
103. Calvo, K.R.; Sykes, D.B.; Pasillas, M.; Kamps, M.P. Hoxa9 Immortalizes a Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Promyelocyte Capable of Biphenotypic Differentiation to Neutrophils or Macrophages, Independent of Enforced Meis Expression. *Mol. Cell. Biol.* 2002, 20, 3274–3285.
104. Hu, Y.L.; Passegué, E.; Fong, S.; Largman, C.; Lawrence, H.J. Evidence that the Pim1 kinase gene is a direct target of HOXA9. *Blood* 2007, 109, 4732–4738.
105. Stadler, C.R.; Vegi, N.; Mulaw, M.A.; Edmaier, K.E.; Rawat, V.P.S.; Dolnik, A.; Bullinger, L.; Heilmeier, B.; Quintanilla-Fend, L.; Spiekermann, K.; et al. The leukemogenicity of Hoxa9 depends on alternative splicing. *Leukemia* 2014, 28, 1838–1843.
106. Dintilhac, A.; Bihan, R.; Guerrier, D.; Deschamps, S.; Pellerin, I. A conserved non-homeodomain Hoxa9 isoform interacting with CBP is co-expressed with the “typical” Hoxa9 protein during embryogenesis. *Gene Expr. Patterns* 2004, 4, 215–222.
107. Vijapurkar, U.; Fischbach, N.; Shen, W.; Brandts, C.; Stokoe, D.; Lawrence, H.J.; Largman, C. Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation. *Mol. Cell. Biol.* 2004, 24, 3827–3837.
108. Huang, Y.; Sitwala, K.; Bronstein, J.; Sanders, D.; Dandekar, M.; Collins, C.; Robertson, G.; MacDonald, J.; Cezard, T.; Bilenky, M.; et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. *Blood* 2012, 119, 388–398.
109. Zhong, X.; Prinz, A.; Steger, J.; Garcia-Cuellar, M.P.; Radsak, M.; Bentaher, A.; Slany, R.K. HoxA9 transforms murine myeloid cells by a feedback loop driving expression of key oncogenes and cell cycle control genes. *Blood Adv.* 2018, 2, 3137–3148.
110. Dorsam, S.T.; Ferrell, C.M.; Dorsam, G.P.; Derynck, M.K.; Vijapurkar, U.; Khodabakhsh, D.; Pau, B.; Bernstein, H.; Haqq, C.M.; Largman, C.; et al. The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells. *Blood* 2004, 103, 1676–1684.
111. Calero-Nieto, F.J.; Joshi, A.; Bonadies, N.; Kinston, S.; Chan, W.-I.; Gudgin, E.; Pridans, C.; Landry, J.-R.; Kikuchi, J.; Huntly, B.J.; et al. HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias. *Oncogene* 2013, 32, 5471–5480.

112. Shah, C.A.; Bei, L.; Wang, H.; Platanias, L.C.; Eklund, E.A. HoxA10 Protein Regulates Transcription of Gene Encoding Fibroblast Growth Factor 2 (FGF2) in Myeloid Cells. *J. Biol. Chem.* 2012, 287, 18230–18248.
113. Steger, J.; Füller, E.; Garcia-Cuellar, M.-P.; Hetzner, K.; Slany, R.K. Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation. *Leukemia* 2015, 29, 901–908.
114. Brumatti, G.; Salmanidis, M.; Kok, C.H.; Bilardi, R.A.; Sandow, J.J.; Silke, N.; Manson, K.; Visser, J.; Jabbour, A.M.; Glaser, S.P.; et al. HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. *Oncotarget* 2013, 4, 1933–1947.
115. Faderl, S.; Kantarjian, H.; Estey, E.; Manshouri, T.; Chan, C.; Rahman, E.A.; Kornblau, S.; Cortes, J.; Thomas, D.; Pierce, S.; et al. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. *Cancer* 2000, 89, 1976–1982.
116. Hess, J.L.; Bittner, C.B.; Zeisig, D.T.; Bach, C.; Fuchs, U.; Borkhardt, A.; Frampton, J.; Slany, R.K. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. *Blood* 2006, 108, 297–304.
117. Sun, Y.; Zhou, B.; Armstrong, S.A.; Dou, Y.; Hess Correspondence, J.L.; Mao, F.; Xu, J.; Miao, H.; Zou, Z.; Tran, L.; et al. HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis In Brief Cancer Cell HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. *Cancer Cell* 2018, 34.
118. Moskow, J.J.; Bullrich, F.; Huebner, K.; Daar, I.O.; Buchberg, A.M. Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. *Mol. Cell. Biol.* 1995, 15, 5434–5443.
119. Hurley, L.H. DNA and its associated processes as targets for cancer therapy. *Nat. Rev. Cancer* 2002, 2, 188–200.
120. Thorsteinsdottir, U.; Kroon, E.; Jerome, L.; Blasi, F.; Sauvageau, G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. *Mol. Cell. Biol.* 2001, 21, 224–234.

Retrieved from <https://encyclopedia.pub/entry/history/show/32940>